Clinical trial
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In…
NCT00369382 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00369382 |
|---|---|
| Title | Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients |
| Official title | A Randomized Open-Label Study To Compare The Safety And Efficacy Of Conversion From A Calcineurin Inhibitor To Sirolimus Vs Continued Use Of A Calcineurin Inhibitor In Heart Transplant Recipients With Mild-Moderate Impaired Renal Function |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Graft Rejection, Kidney Failure |
| Intervention type | Drug |
| Interventions | cyclosporine or tacrolimus, sirolimus |
| Enrollment | 121 |
| Start date | Sep 1, 2006 |
| Primary completion | Apr 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Aug 29, 2006 |
| Last update posted | May 30, 2011 |
| Countries | Australia, Austria, Canada, New Zealand, Spain, Switzerland, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: